Explore our solutions
Featured resources
Frequently Asked Questions
-
How do cord-blood CD34+ cells differ from peripheral-blood or bone-marrow CD34+ cells?
CD34+ cells derived from umbilical cord blood (UCB) offer several advantages compared to those obtained from other sources of CD34+ cells including:
- Rapid availability
- More naïve/primitive than other sources
- ten-fold great number in cord blood and on peripheral blood
- Increased capacity for self-renewal
-
Which research applications are best suited for umbilical CD34+ stem cells?
Potential research applications include:
- Molecular genetics
- Angiogenesis
- Regenerative medicine
- Immune diseases
- Gene editing/CRISPR
- Validating expansion technology
- Cellular therapy research
-
What is the difference between CD34+ hematopoietic stem cells (HSCs) and hematopoietic stem and progenitor cells (HSPCs)?
Hematopoietic stem cells (HSCs) are rare self-renewing cells capable of long-term blood system reconstitution. Hematopoietic progenitor cells (HPCs) are downstream descendants with more limited differentiation potential.
Hematopoietic stem and progenitor cells (HSPCs) is the broader term used to describe the mixed CD34+ cell populations commonly used in transplantation, gene editing, and cell therapy research.
-
What markers define HSPCs?
Human hematopoietic stem and progenitor cells (HSPCs) are typically defined by CD34 expression and comprise a spectrum of stem and progenitor cell populations with varying degrees of self-renewal and differentiation capacity.
Phenotypic characterization using markers such as CD38, CD90, CD45RA, and CD49f allows further identification of primitive stem cell subsets.
In particular, CD34+CD38− cells are enriched for early hematopoietic progenitors, while the CD34+CD38−CD90+CD45RA− immunophenotype is widely recognized as a marker profile associated with long-term hematopoietic stem cells capable of sustained multilineage reconstitution following transplantation.
